Approved indications: Omidria is FDA-approved for use in adults to maintain pupil size (mydriasis), prevent pupil constriction (miosis), and reduce postoperative ocular pain during cataract surgery or intraocular lens replacement.

Off-label uses: Off-label use is uncommon and generally limited to similar anterior segment procedures at the surgeon’s discretion; there is limited formal evidence for other indications compared with its approved use.

Efficacy expectations: Omidria acts during surgery, helping keep the pupil stable throughout the procedure and reducing the need for mechanical pupil expansion devices; patients typically experience less early postoperative eye pain and inflammation compared with irrigation solutions without Omidria. In clinical studies, it reduced the incidence and magnitude of intraoperative miosis and decreased early postoperative pain, offering an advantage over standard irrigation alone but serving as an adjunct rather than a replacement for other anti-inflammatory eye drops.

Typical dosing and administration: For adults, the standard dose is 4 mL of Omidria added aseptically to 500 mL of balanced salt solution or another approved ophthalmic irrigation solution, mixed thoroughly, and used to irrigate the anterior chamber during cataract surgery or intraocular lens replacement. The solution is administered only by the surgical team directly into the eye during the procedure; there is no self-administration by the patient and no oral or topical home dose.

Special dosing instructions: The diluted solution should be prepared immediately before use and used in a single surgical case; it should not be combined with other drugs in the same irrigation solution unless specified by the manufacturer. The surgeon may adjust the volume of irrigation used depending on the procedure but does not typically change the drug concentration.

Missed dose and overdose: Because Omidria is given once during surgery, a “missed dose” does not apply; if it is not used, standard irrigation and other intraoperative or postoperative medications are employed instead. Overdose is unlikely in routine practice, but excessive intraocular exposure could theoretically increase local side effects or intraocular pressure; management is supportive, guided by the ophthalmic surgeon.

Common side effects: The most frequently reported effects are related to eye surgery itself, including eye irritation, increased intraocular pressure, mild eye pain, light sensitivity, and inflammation; these are usually temporary and mild to moderate in severity.

Serious or rare adverse effects: Rarely, patients may experience significant elevation of intraocular pressure, severe eye inflammation, or hypersensitivity reactions such as eye redness, swelling of the eyelids, or systemic allergic symptoms; any sudden vision loss, severe eye pain, marked redness, or swelling after surgery requires immediate medical attention.

Warnings and precautions: Because phenylephrine is a vasoconstrictor, caution is advised in patients with uncontrolled hypertension, significant cardiovascular disease, or those receiving other adrenergic agents, although systemic exposure from intraocular use is low. Ketorolac is a nonsteroidal anti-inflammatory drug (NSAID), so use with caution in patients with known NSAID hypersensitivity, bleeding disorders, or those at high risk for poor corneal healing. Safety in pregnancy and breastfeeding has not been well established; use is typically limited to situations where the expected benefit outweighs potential risks. Omidria is approved for adults; pediatric use should follow specialist judgment.

Comparative safety: Compared with using irrigation solution alone, Omidria adds potential NSAID- and adrenergic-related risks but at very low systemic exposure; overall, when used as directed by surgeons, its safety profile is considered acceptable and similar to other intraocular adjuncts.

Side effect reporting and safety updates: Patients should report any concerning symptoms to their eye surgeon or ophthalmologist; adverse events can be reported to the FDA MedWatch program, and updated safety information is available through FDA safety communications and the product’s prescribing information.

Drug and supplement interactions: Systemic interactions are unlikely because Omidria is administered locally in the eye and systemic absorption is very low. However, due to phenylephrine, surgeons may exercise caution in patients taking other adrenergic agonists, monoamine oxidase inhibitors, or strong blood pressure medications. Ketorolac may theoretically add to the effects of other NSAIDs, anticoagulants, or antiplatelet agents on bleeding risk, though this risk is minimal with intraocular use.

Food, alcohol, and procedure interactions: There are no known interactions with food or alcohol specific to Omidria, as it is not taken by mouth. It is used only during eye surgery and does not interfere with imaging or diagnostic procedures outside the operative setting.

Precautions and conditions requiring caution: Caution is advised in patients with severe uncontrolled hypertension, significant cardiovascular disease, or known hypersensitivity to phenylephrine, ketorolac, other NSAIDs, or any component of the product. Patients with bleeding disorders, on strong blood thinners, or with corneal epithelial disorders may require individualized risk–benefit assessment.

Monitoring needs: During and after surgery, the ophthalmic team monitors pupil size, intraocular pressure, corneal status, vision, and symptoms such as pain or inflammation. No routine blood tests or ECG monitoring are required solely because Omidria is used.

Q: What is Omidria used for during cataract surgery?
A: Omidria is added to the irrigation fluid used in cataract or lens replacement surgery to help keep the pupil wide and to reduce pain and inflammation after the procedure.

Q: Will I need to use Omidria at home after surgery?
A: No, Omidria is given only once during surgery by the eye surgeon; afterward, you may be prescribed separate eye drops such as antibiotics or anti-inflammatory medicines for home use.

Q: Does Omidria replace my postoperative anti-inflammatory eye drops?
A: No, Omidria works during surgery and early recovery, but most patients still need standard postoperative eye drops as prescribed by their ophthalmologist.

Q: Are there serious risks with Omidria?
A: Serious problems are uncommon; most side effects relate to the surgery itself, but rarely there can be high eye pressure, severe inflammation, or allergic reactions, which your surgical team watches for closely.

Q: Can Omidria affect my blood pressure or heart condition?
A: Systemic absorption is low, but because it contains phenylephrine, your surgeon may take extra precautions if you have uncontrolled high blood pressure or significant heart disease and will monitor you during and after surgery.